Amphora Medical

The company's core product was the Selective Bladder Denervation System, a minimally invasive, cystoscopic device. This system utilized radiofrequency ablation, a procedure involving targeted heat, to dampen the nerve signals in the bladder responsible for OAB symptoms. A key feature of this technology was its selectivity; it was designed to target only the nerves causing the overactive symptoms while preserving the nerves required for normal bladder function. The procedure aimed to offer a lasting improvement in symptoms and restore bladder function for patients with few other effective options.

Amphora Medical's business model revolved around the development and eventual commercialization of this medical device, contingent on clinical trial success and regulatory approval. The company successfully navigated several funding rounds to finance its research and development. It secured a Series A round in 2013 and 2015, followed by a significant $35.5 million Series B financing in 2017. This later round was co-led by Longitude Capital and Boston Scientific, with participation from other venture investors, and was intended to fund a U.S. pivotal study of its denervation system. Ultimately, the company was reported as acquired in May 2019.